Mono-dga-rfb4
As of the edition of 20 October 2026, Mono-dga-rfb4 is a drug: went quiet in 2000; acts on CD22.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Went quiet, 2000
- Kind
- Unknown
- Registered trials
- 1, 0 stopped early
- Disease areas
- Blood and lymph; Cancer; Immune system; Infections
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD22 | B-cell receptor CD22 | P20273 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase 1 | 1 | 1 | 0 | 0 |
| All trials | 1 |